We have developed a sensitive, specific solid-phase immunoradiometric assay (IRMA) of parathyroid hormonerelated protein (PTH-RP) with use of affinity-purifiedpolyclonal immunoglobulins. Antibodies recognizing PTH-RP(37-74) are immobilized to a polystyrene bead to "capture" analytes from the sample; antibodiesto epitopes within the 1-36 amino acid region of PTH-RP are labeled with 1251 This uvi recognizes PTH-RP(1-74) and PTH-RP(1-86) equivalently, but does not detect N-terminal or C-terminal fragments of PTH-RP, intact human parathynn (PTH), or fragments of PTH. PTH-RP is not stable in plasma at 3-5 #{176}C or room temperature, but a mixture of aprotinin (500 kallikrein units/L) and leupeptin (2.5 mg/L) improves PTH-RP stability in blood samples. In plasma collected in the presence of these protease inhibitorsfrom normal volunteers and patients with various disorders of calcium metabolism, PTH-RP concentrations were above normal (>1.5 pmol/L) in 91% (42 of 46) of patients with hypercalcemia associated with nonhematological malignancy. In plasma from patients with other hypercalcemic conditions(e.g., primary hyperparathyroidism,sarcoidosis, and vitamin D excess), PTH-RP was undetectable.Abovenormal concentrations of PTH-RP and total calcium decreased to normal in a patient with an ovarian cyst adenocarcinoma after surgical removal of the tumor. We conclude that PTH-RP is related to and probablythe causative agent of hypercalcemia in most patients with cancer, and that measurements of PTH-RP are useful in the diagnosis and management of patients with tumor-associatedhypercalcemia. 
The rabbit antibodies to PTH-RP(1-74) were adSorbed and eluted in 0.2 moth. glycine. HO buffer at several pHvalues, or with one pHelution, and used in the RIAseparately. The antibody concentration used was similar for allthe fractions, as detatminedby percentbinding(Bm. PTH-RP(1-44) was used as the standard. 0, AntIbodieseluted from the affinity column at pH 2.5; A, at pH3.0; X, at pH 3.5. ----. Antibodies eluted Inone-step elution procedure at pH 2.5
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(12). The specific activity of the product varied from 75 to 150 Ci/g. The radiolabeled gamma globulin is stable for at least six weeks.
Affinity Purificationof SpecificAntibodies
Human PTH-RP and human FFH-RP(37-74) immunoaflinity resins were prepared by coupling 1 mg of human or human to 1 g of CNBr-activated Sepharose 4B. Protein A affinity columns were prepared by coupling Protein A to Sepharose 4B (13). Polyclonal rabbit antiserum elicited by immunizations with human PTH-RP(1-74) was affinity-purified into two classes: one specific for PTH-RP(1-36), the other specific for PTH-RP(37-74). Antiserum that failed to absorb was adsorbed onto an affinity column with immobilized human PTH-RP(37-74).
The adsorbed antibodies were eluted with glycine HC1 and further purified by using Protein A-Sepharose as described above. The highaffinity antibodies were then assessed for sensitivity and yield by use of lmIlabeled per liter, 10 mmol of sodium phosphate buffer (pH 7.4), 154 mmol of sodium chloride, 1 g of BSA, 1 mL of Thton X-100, 50 mL of normal rabbit serum, 39.4mg of aprotinin, and 2.4mg of leupeptin. We routinely diluted the standard in the assay buffer to 0.5, 1.0, 2.0, 10, 50, 100, 500, and 1000 pmol/L.
Assay Procedure
We performed the IRMA and ascites underwent surgery, at which time ascites fluid, ovarian cyst fluid, and ovarian vein blood samples were collected.
Results

Assay Validation
The immobilized anti-PTH-RP(37-74) to noise (counts/mm for the zero standard) ratio was 2.
This IRMA is specific for PTH-RP: it does not recognize 
ClinicalCorrelations
Determination of a normal range for PTH-RP was based on the assay of plasma samples from 69 volunteers.
Thirty-five of these subjects had detectable concentrations of F1'H-RP, the median concentration being 0.4 pmol/L. The remRining subjects had undetectable concentrations of PTH-RP (<0.2 pmol/L). No sample had values >1.5 pmol/L, which we established as the upper limit of normal (Figure 3) . Table 5 To check the clinical specificity of the PTH-RP assay, we analyzed plasma samples from hypercalcemic patients with primary hyperparathyroidism, sarcoidosis, and vitamin D toxicity. All samples contained FFH-RP at concentrations <1 pmol/L (Figure 3) . Patients with chronic renal failure frequently showed increased values of PTH, but the PTH-RP concentrations were within the normal range (<1.5 pmol/L). Although the concentration of FFH-RP is measurable in blood from some patients with chronic renal failure, impaired renal function does not appear to reduce the clearance of large P'FH-RP peptides (larger than 74 amino acids).
DiscussIon
This IRMA of PTH-HP has several advantages over the assays previously reported (8) (9) (10) (11) 17) . It has greater sensitivity and improved specificity, both analytically and clinically. The analytical sensitivity is 0.1 pmol/L, compared with 2 to lOpmoI/L for PTH-RP RIAs (10) (11) (12) and 1 pmol/L described by Burtis et (Figure 1) . The antibodies eluted with low pH (2.5) from the affinity column had greater affinity than the antibodies eluted at pH 3.0 or 3.5. When the highaffinity antisera were used for both capture and radiolabeling, the sensitivity of our assay was improved to 0.1 pmol/L, whereas the sensitivity of the IRMA performed with antiserum eluted at pH 3.5 was 0.5 pmoLfL. Use of antiserum eluted with the one-step elution procedure (at pH 2.5) described by Burtis et al. (8) yielded a sensitivity of 0.5 pmol/L. 2. We used macroscopic (8-mm-diameter) beads in the IRMA. This permits extensive washing, which reduces nonspecific binding. Moreover, the 8-mm beads have a high capacity, resulting in high binding of radioactive antibodies.
3. We used assay buffer as the matrix to dilute the standard. The assay matrix, the constituents of which are all common reagents, provided more consistent results. Its use also reduced nonspecific binding and helped enhance the sensitivity.
The assay also showed improved clinical sensitivity in the diagnosis of patients with hypercalcemia of malignancy. We found that 91% of our hypercalcemia patients with solid malignancies had above-normal concentrations of PTH-RP, compared with 20-60% reported by others (8-11, 17) . We attribute this to the improved analytical sensitivity of the assay and also to the use of preservatives during blood collection. It seems unlikely that these differences are entirely due to the selection of patients, although some of the samples in our study were analyzed retrospectively.
However, the mean concentration of PTH-RP in patients with humoral hypercalcemia of malignancy (22.2 pmol/L) was similar to sayed the samples collected with and without preserva- (ma. in preparation). The assay we describe also had improved specificity, it did not cross-react with FI'H-RP fragments or with FF11 or its fragments. This specificity has not been attained in the assays described previously (8, 11). The improved specificity is due to use of affinity-column-purified polyclonal antibodies. Anti-FrH-RP(1--36)
had no cross-reaction with PTH-RP(37-74), as shown by its failure to bind 'I-labeled PTH-RP(37-74). Similarly, anti-PTH-RP(37-
76)
was not contaminated with anti-FFH-RP(1-36). FF11-HP concentrations in patients with primary hyperparathyroidism and secondary hyperparathyroidism (chronic renal failure), and in calcium disorders unrelated to excessive PTH secretion, such as sarcoidosis and vitamiii D excess, were indistinguishable from those found in normal subjects. Two patients with malignancy had above-normal VFH attributable to the coexistence of primary hyperparathyroidism with malignancy; however, this increase was not due to cross-reactivity-in the assay. The patient with leukemia with above-normal FF11 and low Fm-HP could not be confirmed for primary hyperparathyroidism.
The finding that FF11-HP is present in many normal subjects (Figure 3) confirms some previous reports indicating that Fm-HP circulates in the blood of normal subjects, where it presumably is involved in regulating functions that are currently not understood. Further work is required to clarify whether the failure to detect FF11-HP in all normal subjects is due to lack of assay sensitivity or indicates that some individuals do not have FF11-HP in their blood.
The patients with hypercalcemia and squamous cell carcinomas nearly all had above-normal concentrations of FF11-HP. Additionally, we found above-normal PTH-HP in 88% of nonsquamous cell carcinoma. Fm-HP was very high (222.4 mmolJL) in one of the breast cancer patients-a value that was confirmed by repeated assays and in dilution studies, in which results for the diluted sample paralleled the standard curve. This patient had extensive metastasis of breast cancer to liver and lung, and had a high calcium concentration (3.3 mmol/L).
PTH-RP
is not frequently increased in hematological
We conclude that this IRMA could be useful in the differential diagnosis of patients with hypercalcemia. Clearly, quantification of Fm-HP could be used with FF11 measurements in the differential diagnosis of patients with hyperca!cemia. Our studies also suggest that the assay may be used to monitor patients with abovenormal Fm-HP after treatment.
Addendum added in revision. Recently, Ratcliffe et al. (18) reported an IRMA involving a monoc!onal antibody to FFH-RP(1-34) coupled to cellulose particles as the capture antibody and a rabbit anti-FFH-RP(37-67)
as the radiolabeled antibody. The detection limit is 0.23 pmol/L, compared with 0.1 pmol/L in our assay. The authors reported above-normal concentrations of Fm-HP in 95% of their selected patients with hypercalcemia of malignancy. Plasma samples from normal subjects and patients with primary hyperparathyroidism had undetectable concentrations of FFH-RP. We have shown low but detectable concentrations of FFH-RP in some normal subjects. Ratcliffe et al. collected samples without protease inhibitors, and results for the normal samples were less than for the zero standard, indicating a matrix effect. Highly sensitive PTH-RP assays are required to resolve whether normal samples contain Fm-HP or not.
